Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

被引：8

作者：

Elstrom, Rebecca L. ^{[1
]}

Ruan, Jia ^{[1
]}

Christos, Paul J. ^{[2
]}

Martin, Peter ^{[1
]}

Lebovic, Daniel ^{[4
]}

Osborne, Joseph ^{[3
]}

Goldsmith, Stanley ^{[3
]}

Greenberg, June ^{[1
]}

Furman, Richard R. ^{[1
]}

Avram, Anca ^{[5
]}

Putman, Ryan ^{[4
]}

Chapman, Erica ^{[4
]}

Mazumdar, Madhu ^{[2
]}

Griffith, Kent ^{[6
]}

Coleman, Morton ^{[1
]}

Leonard, John P. ^{[1
]}

Kaminski, Mark S. ^{[4
]}

机构：

[1] Weill Cornell Med Coll, Div Hematol Oncol, Dept Med, New York, NY USA

[2] Weill Cornell Med Coll, Dept Publ Hlth, Div Biostat & Epidemiol, New York, NY USA

[3] Weill Cornell Med Coll, Dept Radiol, Div Nucl Med, New York, NY USA

[4] Univ Michigan, Sch Med, Dept Med, Div Hematol Oncol, Ann Arbor, MI 48104 USA

[5] Univ Michigan, Sch Med, Div Nucl Med, Dept Radiol, Ann Arbor, MI USA

[6] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI USA

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 02期

关键词：

Lymphoma; radioimmunotherapy; radiosensitization; proteasome; ANTI-CD20; MONOCLONAL-ANTIBODY; IODINE I-131 TOSITUMOMAB; LATE-ONSET TOXICITIES; LOW-GRADE; IBRITUMOMAB TIUXETAN; MULTIPLE-MYELOMA; MANTLE CELL; THERAPY; EFFICACY; TRIALS;

D O I：

10.3109/10428194.2014.914195

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with I-131-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m(2) bortezomib, in combination with a standard dose of 75 cGy I-131-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with I-131-tositumomab with promising response rates.

引用

页码：342 / 346

页数：5

共 21 条

[1] A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma [J].

Beaven, Anne W. ;

Shea, Thomas C. ;

Moore, Dominic T. ;

Feldman, Tatyana ;

Ivanova, Anastasia ;

Ferraro, Madlyn ;

Ford, Peggy ;

Smith, Judith ;

Goy, Andre .

LEUKEMIA & LYMPHOMA, 2012, 53 (02) :254-258

[2] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation [J].

Beers, Stephen A. ;

Chan, Claude H. T. ;

James, Sonya ;

French, Ruth R. ;

Attfield, Kathrine E. ;

Brennan, Claire M. ;

Ahuja, Anupama ;

Shlomchik, Mark J. ;

Cragg, Mark S. ;

Glennie, Martin J. .

BLOOD, 2008, 112 (10) :4170-4177

[3] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[4] Sequential designs for phase I clinical trials with late-onset toxicities [J].

Cheung, YK ;

Chappell, R .

BIOMETRICS, 2000, 56 (04) :1177-1182

[5]

Chu PG, 2002, LEUKEMIA LYMPHOMA, V43, P2335, DOI 10.1080/1042819021000040044

[6] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

[7] Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma [J].

Di Bella, Nicholas ;

Taetle, Raymond ;

Kolibaba, Kathryn ;

Boyd, Thomas ;

Raju, Robert ;

Barrera, David ;

Cochran, Ernest W., Jr. ;

Dien, Philip Y. ;

Lyons, Roger ;

Schlegel, Peter J. ;

Vukelja, Svetislava J. ;

Boston, Julie ;

Boehm, Kristi A. ;

Wang, Yunfei ;

Asmar, Lina .

BLOOD, 2010, 115 (03) :475-480

[8] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[9] PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis [J].

Goel, A ;

Dispenzieri, A ;

Greipp, PR ;

Witzig, TE ;

Mesa, RA ;

Russell, SJ .

EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) :784-795

[10] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma [J].

Goy, A ;

Younes, A ;

McLaughlin, P ;

Pro, B ;

Romaguera, JE ;

Hagemeister, F ;

Fayad, L ;

Dang, NH ;

Samaniego, F ;

Wang, M ;

Broglio, K ;

Samuels, B ;

Gilles, F ;

Sarris, AH ;

Hart, S ;

Trehu, E ;

Schenkein, D ;

Cabanillas, F ;

Rodriguez, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :667-675

← 1 2 3 →